CDDO Methyl Ester

CDDO Methyl Ester (bardoxolone methyl) is a semi-synthetic triterpenoid developed from the oleanolic acid scaffold that induces apoptosis and differentiation in tumor cells. Agonist of the KEAP1-Nrf2 pathway, thus inducing expression of antioxidant proteins and protection against oxidative damage from injury and inflammation. Also an antagonist of the NF-kB pro-inflammatory transcription factor. Clinical trials are currently underway for type 2 diabetes treatment, due to its potent antidiabetic activity, but was confirmed to enhance cardiac disease during a phase 2 trial in October 2012.

Catalog No. Size Price Quantity
92-1147 5 mg $259.00

Please contact Customer Service at for European (EUR) or United Kingdom (GBP) pricing or log in to see your account-specific pricing.
CDDO Methyl Ester
Compound Type
Cells were plated in a 384-well plate and incubated overnight at 37°C/5% CO₂ to allow the cells to attach and grow. Cells were then stimulated with a control compound, using the assay conditions described below. Following stimulation, signal was detected using the PathHunter Detection Kit according to the recommended protocol.